Revolutionizing the Treatment of Age‑Related Diseases
The global population is rapidly aging, leading to a growing incidence of age‑related diseases.
Obesity, cardiac disease, and type‑2 diabetes cost over $200 billion annually in the United States alone.
Loss of mitochondrial mass is a major driver of decreased metabolic rate and age‑related energy imbalance.
OUR TECHNOLOGY
Bionic Discovery Platform

HIGH THROUGHPUT BIOLOGY
Tissue Dynamics' advanced robotic automation platform allows for the formation, tracking, and long-term study of over 20,000 human organoids in parallel. The system eliminates human error and drastically reduces technical variability.

ADVANCED SENSOR TECHNOLOGY
The DynamiX platform enables the real-time readout of human organoid metabolism and function under physiological conditions, providing critical insight into the dynamics and mechanism of disease.

DISCOVERY & GENERATION
The MechaniX software suite reconstructs metabolic networks and process dynamics to identify novel targets, generate unique assets, and predict human-relevant toxicity with over 95% accuracy.

Disruptive Drug Development
FIRST IN CLASS THERAPEUTICS
UNRAVELING THE MECHANISMS OF DISEASE

OUR ASSETS
In development
PROGRAM
TARGET
INDICATION
STAGE OF DEVELOPMENT
PARTNER
TD02-OVL5
UBL5
Obesity/CBD
Preclin
IND
Phase I
Phase II
Phase III

TD07-AFC2
SCD-1 & PPARA
Cardiac Fibrosis
Preclin
IND
Phase I
Phase II
Phase III

TD06-MMT6
AMPK
Arrhythmia
Preclin
IND
Phase I
Phase II
Phase III

TD30-EVO2
BTK & PPARG
Multiple Sclerosis
Preclin
IND
Phase I
Phase II
Phase III

STAGE OF DEVELOPMENT
Preclin
IND
Phase I
Phase II
Phase III
TARGET
UBL5
PARTNER

PROGRAM
TD02-OVL5
INDICATION
Obesity/CBD
STAGE OF DEVELOPMENT
Preclin
IND
Phase I
Phase II
Phase III
TARGET
SCD-1 & PPARA
PARTNER

PROGRAM
TD07-AFC2
INDICATION
Cardiac Fibrosis
STAGE OF DEVELOPMENT
Preclin
IND
Phase I
Phase II
Phase III
TARGET
AMPK
PARTNER

PROGRAM
TD06-MMT6
INDICATION
Arrhythmia
STAGE OF DEVELOPMENT
Preclin
IND
Phase I
Phase II
Phase III
TARGET
BTK & PPARG
PARTNER

PROGRAM
TD30-EVO2
INDICATION
Multiple Sclerosis
OUR PARTNERS
Collaborations and Partnerships





